252 related articles for article (PubMed ID: 12651195)
1. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines.
Duffy MJ; van Dalen A; Haglund C; Hansson L; Klapdor R; Lamerz R; Nilsson O; Sturgeon C; Topolcan O
Eur J Cancer; 2003 Apr; 39(6):718-27. PubMed ID: 12651195
[TBL] [Abstract][Full Text] [Related]
2. Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer.
Carpelan-Holmström M; Haglund C; Lundin J; Alfthan H; Stenman UH; Roberts PJ
Br J Cancer; 1996 Sep; 74(6):925-9. PubMed ID: 8826859
[TBL] [Abstract][Full Text] [Related]
3. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
4. The association of preoperative serum tumour markers with Dukes' stage and survival in colorectal cancer.
Lindmark G; Bergström R; Påhlman L; Glimelius B
Br J Cancer; 1995 May; 71(5):1090-4. PubMed ID: 7734306
[TBL] [Abstract][Full Text] [Related]
5. Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer.
Carpelan-Holmström M; Haglund C; Lundin J; Järvinen H; Roberts P
Eur J Cancer; 1996 Jun; 32A(7):1156-61. PubMed ID: 8758246
[TBL] [Abstract][Full Text] [Related]
6. Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer.
Louhimo J; Carpelan-Holmström M; Alfthan H; Stenman UH; Järvinen HJ; Haglund C
Int J Cancer; 2002 Oct; 101(6):545-8. PubMed ID: 12237895
[TBL] [Abstract][Full Text] [Related]
7. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.
J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347
[TBL] [Abstract][Full Text] [Related]
8. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2935-8. PubMed ID: 9329568
[TBL] [Abstract][Full Text] [Related]
9. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
[TBL] [Abstract][Full Text] [Related]
10. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
11. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.
Duffy MJ; van Dalen A; Haglund C; Hansson L; Holinski-Feder E; Klapdor R; Lamerz R; Peltomaki P; Sturgeon C; Topolcan O
Eur J Cancer; 2007 Jun; 43(9):1348-60. PubMed ID: 17512720
[TBL] [Abstract][Full Text] [Related]
12. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
Nicolini A; Caciagli M; Zampieri F; Ciampalini G; Carpi A; Spisni R; Colizzi C
Cancer Detect Prev; 1995; 19(2):183-95. PubMed ID: 7750106
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of predictive markers for patients with advanced colorectal cancer.
Byström P; Berglund Å; Nygren P; Wernroth L; Johansson B; Larsson A; Glimelius B
Acta Oncol; 2012 Sep; 51(7):849-59. PubMed ID: 22974092
[TBL] [Abstract][Full Text] [Related]
15. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885
[TBL] [Abstract][Full Text] [Related]
16. Tumor markers in staging and prognosis of colorectal carcinoma.
Levy M; Visokai V; Lipska L; Topolcan O
Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
[TBL] [Abstract][Full Text] [Related]
17. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
Jing JX; Wang Y; Xu XQ; Sun T; Tian BG; Du LL; Zhao XW; Han CZ
Asian Pac J Cancer Prev; 2014; 15(23):10267-72. PubMed ID: 25556459
[TBL] [Abstract][Full Text] [Related]
18. Correlation of the Serum Level of Carcinoembryonic Antigen and Prolactin with Different Stages of Colorectal Carcinoma According to Dukes' Staging.
Rahman MR; Sheikh SH; Lima IJ; Islam MR; Faisal M; Islam MS; Faruk MO; Jalal MT
Mymensingh Med J; 2016 Jan; 25(1):61-5. PubMed ID: 26931251
[TBL] [Abstract][Full Text] [Related]
19. [Standards, options and recommendations for tumor markers in colorectal cancer].
Eche N; Pichon MF; Quillien V; Gory-Delabaere G; Riedinger JM; Basuyau JP; Daver A; Buecher B; Conroy T; Dieu L; Bidart JM; Deneux L;
Bull Cancer; 2001 Dec; 88(12):1177-206. PubMed ID: 11792611
[TBL] [Abstract][Full Text] [Related]
20. The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.
Tokunaga R; Sakamoto Y; Nakagawa S; Yoshida N; Baba H
Surg Today; 2017 May; 47(5):636-642. PubMed ID: 28062920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
